Homepage>Company>Media>Pharma News>2021>Merck's Keytruda scores first-in-class nod in early triple-negative breast cancer despite FDA's prior reluctance
Merck's Keytruda scores first-in-class nod in early triple-negative breast cancer despite FDA's prior reluctance